Sales & Marketing How transparent is the VPAS? The UK’s VPAS – a deal that began on 1st January 2019 and which is due to end on 31st December 2023 – is worth around £7 billion.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
